The 1997 ANAO audit reveals that the industry was focused on comparator selection, the incorporation of wider qualitative economic benefits in the evaluation process, and the need to reduce submission churn to accelerate new listings. Sound familiar? …
The last audit shows why more process will never lead to faster access
July 26, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australia leads the way as Moderna and MSD take personalised cancer vaccine into lung cancer
October 24, 2026 - - Latest News -
Arrotex bets on Recce's Phase 3 gel as diabetic foot infections get harder to treat
October 23, 2026 - - Latest News -
The imperative is to negotiate with the fifth year of the agreement in mind
October 23, 2026 - - Latest News -
The private medicines boom has mostly passed vaccines by, for now
October 23, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News